`
`TRADEMARK
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`
`filed in the U.S. District Court
`for the District of Delaware
`on the following
`[1 Trademarksor
`[#Patents.
`( [1 the patent action involves 35 U.S.C. § 292.):
`
`NOVO NORDISK INC. and NOVO NORDISK A/S
`
`DEFENDANT
`
`AUROBINDO PHARMA USA,INC., AUROBINDO
`PHARMALTD. and EUGIA PHARMA SPECIALTIES
`LTD.
`
`
`
`
`DATE INCLUDED
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`INCLUDED BY
`
`PATENT OR
`TRADEMARK NO.
`
`11 Amendment
`en OF PATENT
`TRADEMARK
`
`C1 Answer
`
`1 Cross Bill
`
`(1 Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`aB
`
`o
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`DECISION/JUDGEMENT
`
`
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`DATE
`
`Copy 1—Uponinitiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Uponfiling document adding patent(s), mail this copy to Director Copy 4—Casefile copy
`
`
`
`Case D22-cv-00295-UNA
`
`Pacument 4 Filed OG/O4/22 Rage 2 of 2 PagelD #: 494
`
`DOCKET NO.
`
`PLAINTIFF
`
`ADDENDUM TO AO 120 (ADDITIONAL PATENTS)
`
`DATE FILED
`
`U.S. DISTRICT COURT
`
`3/4/2022
`
`for the District of Delaware
`DEFENDANT
`
`NOVO NORDISKINC. and
`NOVO NORDISKA/S
`
`
`AUROBINDO PHARMAUSA,INC.,
`AUROBINDO PHARMALTD. and
`EUGIA PHARMASPECIALTIES LTD.
`
`TRADEMRw0.
`OnTRADEMARK
`HOLDER OF PATENT OR TRADEMARK
`
`
`
`6|8,920,383 B2 12/30/2014 Novo Nordisk A/S
`
`
`
`7|9,775,953 B2 10/3/2017 Novo Nordisk A/S
`
`
`
`8|10,220,155 B2 3/5/2019 Novo Nordisk A/S
`
`
`
`9|11,097,063 B2 8/24/2021 Novo Nordisk A/S
`
`
`
`10|RE46,363 E 4/11/2017 Novo Nordisk A/S
`
`
`
`11|7,762,994 B2 7/27/2010 Novo Nordisk A/S
`
`
`
`12|8,114,833 B2 2/14/2012 Novo Nordisk A/S
`
`
`
`13|8,536,122 B2 9/17/2013 Novo Nordisk A/S
`
`
`
`14|8,579,869 B2 11/12/2013 Novo Nordisk A/S
`
`
`
`15|8,684,969 B2 4/1/2014 Novo Nordisk A/S
`
`
`
`16|9,108,002 B2 8/18/2015 Novo Nordisk A/S
`
`
`
`17|9,616,180 B2 4/11/2017 Novo Nordisk A/S
`
`
`
`18|9,861,757 B2 1/9/2018 Novo Nordisk A/S
`
`
`
`
`19|10,357,616 B2 7/23/2019 Novo Nordisk A/S
`
`
`
`
`
`
`
`20|10,376,652 B2 8/13/2019 Novo Nordisk A/S
`
`
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`
`
`
`
`
`
`
`
`
`
`
`
`
`INCLUDED BY
`[| Answer [| Other Pleading[] CrossBill
`Amendment
`PATENT OR
`DATE OF PATENT
`TRADEMARK NO.
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`oo
`
`10
`
` DATE INCLUDED
`
`